Myeloproliferative Disorders: Clinical Trials

45 trials for Myeloproliferative Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 9 unknown, 6 terminated, 2 not yet recruiting. 45 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 445Completed 24, Unknown 9, Terminated 6, Not yet recruiting 2, Withdrawn 2, Active not recruiting 1, Recruiting 1

Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders

Trials (filtered) newest first · largest first

All 45 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF)
Phase 4Not yet recruitingSWOG Cancer Research Network2682026-11-012026-09-17
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm
Phase 4WithdrawnPharmaEssentia2026-08-012026-07-31
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
Asciminib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Phase 4CompletedNovartis Pharmaceuticals852024-11-282026-06-08
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
Hydroxyurea - Polycythemia Vera
Phase 4TerminatedNovartis Pharmaceuticals762023-07-282026-08-18
Asciminib Roll-over Study
Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phase 4RecruitingNovartis Pharmaceuticals3472022-08-302026-11-09
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis
Ruxolitinib - Myelofibrosis
Phase 4UnknownQilu Hospital of Shandong University872022-06-102022-07-07
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Flumatinib, Imatinib - CML, Chronic Phase
Phase 4Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.24002022-04-302022-05-10
Ropeginterferon for Treatment Free Remission
Ropeginterferon - CML (Chronic Myelogenous Leukemia)
Phase 4CompletedDong-Wook Kim652021-11-302025-08-22
A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg) - CML, Chronic Phase
Phase 4UnknownJiangsu Hansoh Pharmaceutical Co., Ltd.2002021-11-232022-04-29
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
Flumatinib - Flumatinib, Chronic Myeloid Leukemia, Chronic Phase
Phase 4UnknownShenzhen Second People's Hospital2002021-01-012022-03-16
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Dasatinib - Dasatinib, BCR-ABL
Phase 4UnknownShenzhen Second People's Hospital652019-12-012022-07-27
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
Anagre Cap. - Essential Thrombocythemia
Phase 4CompletedYuhan Corporation702017-06-052021-07-21
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia
Imatinib, Nilotinib - Chronyc Myeloid Leukemia
Phase 4UnknownGruppo Italiano Malattie EMatologiche dell'Adulto4502016-11-112022-01-20
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Dasatinib Tablets - Chronic Myelogenous Leukemia - Chronic Phase
Phase 4CompletedChia Tai Tianqing Pharmaceutical Group Co., Ltd.622016-05-102021-06-14
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Dasatinib 50 MG - Chronic Myelogenous Leukemia
Phase 4UnknownHospital Universitario Dr. Jose E. Gonzalez122016-04-012017-07-13
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
Nilotinib - Chronic Myeloid Leukemia
Phase 4CompletedNovartis Pharmaceuticals1712016-02-182022-07-22
Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
Nilotinib - Leukemia, Chronic Myeloid
Phase 4UnknownSamsung Medical Center402015-04-012015-03-17
CINC424A2X01B Rollover Protocol
ruxolitinib, panobinostat - Primary Myelofibrosis, Polycythemia Vera
Phase 4Active not recruitingNovartis Pharmaceuticals2792015-03-052026-10-19
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Imatinib - Chronic Myeloid Leukemia
Phase 4UnknownCttq902015-02-012014-12-15
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Bosutinib - Previously Treated PH + CML
Phase 4TerminatedPfizer1632014-11-072021-12-30

Showing 20 of 45. Sign in to see all of them.

Narrower conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (29)  ·  Leukemia, Myeloid, Chronic-Phase (8)  ·  Leukemia (5)  ·  Primary Myelofibrosis (4)  ·  Blast Crisis (3)  ·  Bronchiolitis Obliterans Syndrome (3)  ·  Polycythemia Vera (3)  ·  Thrombocythemia, Essential (3)  ·  Gastrointestinal Stromal Tumors (2)  ·  Graft vs Host Disease (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Lymphoma (2)  ·  Myelodysplastic Syndromes (2)  ·  Neoplasms, Plasma Cell (2)

Broader conditions

Hematologic Diseases (45)  ·  Hemic and Lymphatic Diseases (45)  ·  Bone Marrow Diseases (44)  ·  Neoplasms (40)  ·  Neoplasms by Histologic Type (38)  ·  Leukemia, Myeloid (37)  ·  Chronic Disease (36)  ·  Disease Attributes (36)  ·  Pathologic Processes (36)  ·  Pathological Conditions, Signs and Symptoms (36)  ·  Leukemia (33)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7)  ·  Immune System Diseases (6)  ·  Neoplasms by Site (4)

Interventions

nilotinib (14)  ·  Imatinib Mesylate (11)  ·  Dasatinib (5)  ·  ruxolitinib (4)  ·  Hydroxyurea (2)  ·  asciminib (2)  ·  bosutinib (2)  ·  flumatinib (2)  ·  Antilymphocyte Serum (1)  ·  Aspirin (1)  ·  Busulfan (1)  ·  Cyclophosphamide (1)  ·  Filgrastim (1)  ·  Growth Hormone (1)  ·  Interferons (1)

Sponsors

Novartis Pharmaceuticals (17)  ·  Jiangsu Hansoh Pharmaceutical Co., Ltd. (2)  ·  Shenzhen Second People's Hospital (2)  ·  Bristol-Myers Squibb (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  Cttq (1)  ·  Dong-A ST Co., Ltd. (1)  ·  Dong-Wook Kim (1)  ·  Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (1)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Hospital Universitario Dr. Jose E. Gonzalez (1)  ·  King Abdullah International Medical Research Center (1)  ·  PETHEMA Foundation (1)  ·  Pfizer (1)

Countries

United States (11)  ·  China (9)  ·  France (8)  ·  Germany (8)  ·  Canada (7)  ·  Italy (7)  ·  South Korea (7)  ·  Spain (6)  ·  Poland (4)  ·  United Kingdom (4)  ·  Austria (3)  ·  Brazil (3)  ·  Bulgaria (3)  ·  Hungary (3)  ·  India (3)

Top investigators

Jun Ma (2)  ·  Alessandra Iurlo, MD (1)  ·  Alexander Coltoff, MD (1)  ·  Andreas Hochhaus, Professor, MD (1)  ·  Arnon Nagler, MD (1)  ·  Barry R. Meisenberg, MD (1)  ·  Bruno Martino, MD (1)  ·  Carlo Gambacorti-Passerini, MD (1)  ·  Cervantes Francisco, Dr (1)  ·  Chul-won Choi, M.D. (1)  ·  Chul-won Jung, M.D. (1)  ·  Dr. Ahmad S. Alaskar, MD,FACP,FRCP (1)

Results publications

PMID 19720924, PMID 20220063, PMID 21670449, PMID 22198540, PMID 25170123, PMID 26993758, PMID 27771544, PMID 29577674, PMID 30368038, PMID 30912699, PMID 32572189, PMID 33123978, PMID 35235189, PMID 38007586, PMID 38484432, PMID 39164407

NIH funding

2004 (1), 2014 (1), 2015 (1), 2023 (1)